ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1237

Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management

Michael Rosenbluth1, Yifei Dai1, Dianne Shumay1 and Andrea Chadwick2, 1Swing Therapeutics, San Francisco, CA, 2University of Kansas School of Medicine, Kansas City, KS

Meeting: ACR Convergence 2025

Keywords: fibromyalgia, pain, psychosocial factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due to a lack of clinics offering integrated care. Early results from a virtual specialty clinic (Swing Care), augmented by an FDA-cleared digital behavioral therapy (Stanza™), have demonstrated significant improvements at 90 days [4]. The purpose of this analysis is to evaluate six-month outcomes of a digital therapeutic augmented virtual specialty clinic for FM.

Methods: A chart review was conducted with IRB approval and consent waiver (Allendale IRB, Old Lyme, CT). FM patients assessed using the 2016 diagnostic criteria received multimodal treatment, combining non-opioid drug and non-drug therapies, including the option of the digital behavioral therapy. Endpoints collected included Patient Global Impression of Change (PGIC), Fibromyalgia Impact Questionnaire-Revised (FIQ-R), Pain Intensity, and Pain Interference (0-10 Likert Scales). Data were collected at baseline, 2, 4, and 6 months. All patients with at least six-month follow-up data were included in analysis.

Results: Outcomes data were available for 233 patients (Table 1). Baseline FIQ-R total score was 63.6 ± 1.2 [mean ± SE] while baseline pain intensity and pain interference scores were 6.9 ± 0.1 and 7.3 ± 0.1 [mean ± SE], respectively (Table 1). At 2 months, 75.5% of patients reported improvement, with 35.4% much improved or better. At 6 months, 88.0% of patients reported improvement, with 55.4% much improved or better (Figure 1). Average FIQ-R total score was significantly reduced at 6 months (by 14.9 ± 1.1 [mean ± SE] points, p< 0.0001), with significant improvements starting at 2 months (Figure 2). Significant improvements were also observed in FIQ-R Function, Impact, and Symptom domains (p< 0.0001). By six months, pain intensity and pain interference scores were significantly reduced by 1.5 ± 0.1 and 2.0 ± 0.2 [mean ± SE] points, respectively, p values < 0.0001.

Conclusion: Sustained improvements in well-being and reductions in FM severity, pain intensity, and pain interference were demonstrated at the virtual care clinic. These findings highlight the effectiveness of the multidisciplinary approach and the potential of the virtual care clinic as a patient-centered and accessible solution for managing FM.References[1] Buckhardt CS et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview Am Pain Soc (APS); (Clinical Pract Guidel no 4). 2005;4:109.[2] Winslow BT, et al. Fibromyalgia: diagnosis and management. Am Fam Physician. 2023;107(2):137-144.[3] Fitzcharles MA, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag. 2013;18(3):119-126.[4] Shumay D, et al. Society of Behavioral Medicine (SBM) 2024 Annual Meeting.

Supporting image 1Table 1. Cohort characteristics, clinical baseline, and outcomes at 6 months.

Supporting image 2Figure 1. PGIC response rate over time (% participants).

Supporting image 3Figure 2. Changes from baseline on the clinical measures. Error bars = one SE. † p < 0.0100, ‡ p < 0.0010, § p < 0.0001.


Disclosures: M. Rosenbluth: Swing Therapeutics, 12,, 3, 4, 8, 10, 11; Y. Dai: Swing Therapeutics, 2, 11; D. Shumay: Swing Care Provider Group, 3, Swing Therapeutics, 3, 11; A. Chadwick: Scilex Pharmaceuticals, 2, Swing Care Provider Group, 4, 8, Swing Therapeutics, 7, 11, Tonix Pharmaceuticals, 2.

To cite this abstract in AMA style:

Rosenbluth M, Dai Y, Shumay D, Chadwick A. Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/six-month-clinical-outcomes-of-a-digital-therapeutic-augmented-virtual-care-clinic-for-fibromyalgia-management/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/six-month-clinical-outcomes-of-a-digital-therapeutic-augmented-virtual-care-clinic-for-fibromyalgia-management/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology